Health Care Supplies

Alibaba Health and Shentech Biopharmaceuticals Sign Strategic Cooperation Agreement

Assure Tech released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 95.54 M, actual EPS CNY 0.04

JEK released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue CNY 259.17 M, actual EPS CNY 0.1798

Sansure Biotech released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue CNY 375.52 M, actual EPS CNY 0.0296

Alltest released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 203.23 M, actual EPS CNY 0.721

INNOVITA released FY2025 9 Months Earnings on October 30 After-Market BJT: Actual Revenue CNY 330.4 M, Actual EPS CNY 0.9589

BLUE SAIL MEDICAL released FY2025 9 Months Earnings on October 30 Pre-Market (BJT), actual revenue CNY 4.182 B, actual EPS CNY -0.2633

Assure Tech released FY2025 9 Months Earnings on October 30 During-Market (BJT), Actual Revenue CNY 325.29 M, Actual EPS CNY 0.5101

JEK released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue CNY 725.38 M, actual EPS CNY 0.4895

INNOVITA released FY2025 Q3 earnings on October 30 After-Market BJT, actual revenue CNY 53.97 M, actual EPS CNY 0.0443

Jet Bio-Filtration released FY2025 9 Months earnings on October 30 During-Market (BJT), actual revenue CNY 398.18 M, actual EPS CNY 0.4208

Rendu Biotechnology released FY2025 Q3 earnings on October 30 After-Market (BJT), actual revenue CNY 37.91 M, actual EPS CNY 0.1016

Alltest released FY2025 9 Months Earnings on October 30 After-Market BJT, actual revenue CNY 633.08 M, actual EPS CNY 2.3918

Sansure Biotech released FY2025 9 Months Earnings on October 30 After-Market (BJT), Actual Revenue CNY 1.244 B, Actual EPS CNY 0.3102

NANFANG MEDICAL released FY2025 9 Months Earnings on October 30 During-Market BJT, actual revenue CNY 447.31 M, actual EPS CNY -0.0856

BLUE SAIL MEDICAL released FY2025 Q3 earnings on October 30 Pre-Market BJT, actual revenue CNY 1.401 B, actual EPS CNY -0.1526

Jet Bio-Filtration released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 130.04 M, actual EPS CNY 0.0801

NANFANG MEDICAL released FY2025 Q3 earnings on October 30 During-Market (BJT), actual revenue CNY 141.23 M, actual EPS CNY -0.0407

Rendu Biotechnology released FY2025 9 Months Earnings on October 30 After-Market (BJT), actual revenue CNY 119.15 M, actual EPS CNY 0.1616

Autobio released FY2025 9 Months Earnings on October 29 Pre-Market (BJT), actual revenue CNY 3.127 B, actual EPS CNY 1.5034

< 1B

1B - 5B

5B - 10B

10B - 50B

50B - 100B

100B - 500B

500B - 1T

≥ 1T

Market Value

Total Assets

< 100M

100M - 500M

500M - 1B

≥ 100B

Revenue

0 - 50M

50M - 100M

≥ 10B

Profits

< 0%

0% - 5%

5% - 10%

10 - 15%

15% - 20%

20 - 25%

25% - 30%

>= 30%

ROE(TTM)

= 0%

0% - 1%

1% - 3%

3% - 5%

5% - 8%

8% - 10%

>= 10%

Dividend Yield

0% - 10%

10% - 15%

20% - 30%

30% - 40%

40% - 50%

>= 50%

Net Profit Margin

0 - 0.05

0.05 - 0.1

0.1 - 0.2

0.2 - 0.4

0.4 - 0.6

0.6 - 0.8

0.8 - 1

>= 1

Asset Turnover

< 1.5

1.5 - 2

2 - 3

3 - 5

5 - 10

10 - 15

15 - 20

>= 20

Equity Multiplier

< 10%

10% - 30%

30% - 50%

50% - 70%

70 - 80%

80% - 90%

90% - 95%

>= 95%

Debt Ratio

688317

002022

301080

300639

300482

688399

688298

002030

300463

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

Wallstreetcn

LIFERIVER

ACROBIOSYSTEMS

Hybribio Biotech

WONDFO BIOTECH

SSSW

Orient Biotech

DAJY

maccura

688351

02160

02252

00853

688016

02172

MICROPORT opened high today at 6.34%, reaching a maximum of 13.95 yuan. It is currently reported at 13.45 yuan, up 7.95%, with a trading volume of 15.7865 million shares, involving a capital of 213 million yuan. The company recently issued a profit warning, expecting to turn a profit in the fiscal year 2025, with a net profit of no less than 20 million USD, compared to a net loss of 268 million USD in the previous year

AASTOCKS

MICROPORT EP

MP CARDIOFLOW-B

MircroPort Medbot-B

MICROPORT

Endovastec

MICROPORT NEURO

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

512480

300399

512760

588780

159546

300061

588170

CETC Lantian Technology Launches Shanghai IPO

marketscreener

GTJA Allianz CSI All Share Semiconductors & Semiconductor Equipment ETF

TLKJ

Guotai CES Semiconductor Chip Industry ETF

GTJA Allianz SSE STAR Chip Design Thematic ETF

Guotai CSI All Share Integrated Circuit ETF

QITIAN Technology

ChinaAMC SSE STAR Semiconductor Material & Equipment Thematic ETF

CETC Lantian Technology Launches Shanghai IPO

688606

36Kr learned that Alltest announced plans to repurchase company shares for 100 million to 200 million yuan, aimed at reducing registered capital, with a repurchase price not exceeding 85 yuan per share (inclusive)

36Kr

Alltest

Alltest: Plans to repurchase company shares worth 100 million to 200 million yuan

300832

New Industry announced that its myoglobin assay kit has obtained the medical device registration certificate issued by the Guangdong Provincial Drug Administration. This kit is used for the in vitro quantitative determination of myoglobin levels in human serum or plasma, and is clinically used for the auxiliary diagnosis of myocardial infarction. The acquisition of this registration certificate enriches the company's biochemical testing products in the categories of cardiovascular and myocardial markers, which has a positive impact on the company's development, but will not have a significant impact on recent production operations and performance

Snibe

Snibe: The company's myoglobin testing kit has obtained a medical device registration certificate

Shanghai, Jiangsu, and Zhejiang have released the "List of Reform Authorization Items to Support the High-Quality Development of the Yangtze River Delta Ecological Green Integrated Development Demonstration Zone." The document proposes that, under the premise of complying with land spatial planning, the demonstration zone is supported to combine the development needs of new industries and new business formats, allowing for mixed layout and reasonable conversion of land among industrial, warehousing, research and development, and other uses to improve land utilization efficiency

Shanghai, Jiangsu, and Zhejiang issued the "List of Reform Authorization Items to Support the High-Quality Development of the Yangtze River Delta Ecological and Green Integrated Development Demonstration Zone."

The Shanghai Municipal Market Supervision Administration issued the "Guiding Opinions on Promoting the Standardized and Healthy Development of Internet Platform Advertising," emphasizing the strengthening of platform advertising supervision and combating false and illegal advertisements. The opinions support advertising exploration for new industries and new business formats, implementing inclusive and prudent regulation to ensure that advertisements are legal and compliant, especially in areas related to people's life, health, and property safety. At the same time, it proposes to build a collaborative governance system for advertising to address unfair advertising rules and the issue of false advertisements

Shanghai strengthens platform advertising regulation, adopting inclusive and prudent regulatory measures for new industries and new models exploration

300595

AUTEK recently obtained the "Drug Manufacturing License" issued by the Anhui Provincial Drug Administration, valid until December 25, 2030. The company stated that this license will help optimize product structure and promote long-term development, but it will have little impact on operating performance in the short term. The company must complete product registration applications and related inspections before it can commence commercial production and sales. The production and sales of pharmaceutical products are affected by industry policies and market conditions, which carry uncertainties

AUTEK

AUTEK: Obtained the "Drug Manufacturing License"

603658

Autobio Diagnostics' Subsidiary Gets Registration Certificates for 20 Devices

Autobio

Autobio Diagnostics' Subsidiary Gets Registration Certificates for 20 Devices

002371

300604

301101

36Kr learned that the three major A-share indices opened higher collectively, with the Shanghai Composite Index opening up 0.09%, the Shenzhen Component Index up 0.17%, and the ChiNext Index up 0.15%; the semiconductor and AI wearable concepts led the gains, with CCTech and Mingyue Optical Lens rising over 4%, and NAURA rising over 2%; the fluorochemical and stablecoin concepts saw the largest declines, with Digital Certification falling over 5%; new stock N Huadongguang surged 1007.95% on its first day of listing, and N Xinguangyi rose 196.40%

NAURA

CCTech

Mingyue Optical Lens

The three major A-share indices opened higher collectively, and new stock N Hongdongguang surged 1007.95% on its first day of listing

In 2026, the odds of copper will be influenced by the gold-to-copper ratio. Although both copper and gold prices reached historical highs in 2025, the gold-to-copper ratio is at a historical low. The excessive surge in gold prices in 2025 is the core factor driving the rise in copper prices, mainly influenced by the Federal Reserve's monetary easing, the new technology industry cycle, and trade wars. It is expected that copper prices will experience a historically significant increase in 2026

- The article posits that while supply-demand balance explains copper price trends, it cannot resolve betting odds, which are linked to the gold-copper ratio for 2026.  
- Despite reaching historical highs in both copper and gold in 2025, the gold-copper ratio has dropped to a historical low, suggesting that rising gold prices will drive copper prices up in 2026.  
- Factors influencing this rise include U.S. monetary easing, technological industry cycles, and trade war impacts, all expected to reshape demand for copper significantly.

What are the odds of copper? Starting from the extreme copper-gold ratio

688289

Sansure Biotech Gets China Nod for Four Testing Kits

Sansure Biotech

Sansure Biotech Gets China Nod for Four Testing Kits

300888

Winner Medical, parent of Dimora Medical, received the Paid Service Operation Excellence Award at the 2025 Amazon Global Selling Seller Conference. Dimora Medical, a key driver, excelled in Amazon's wound-care category, innovating home-care solutions. Strategic product adjustments and scenario-driven marketing led to success, with rising demand from family physicians and enterprise purchasing. Dimora Medical aims to expand collaborations and strengthen its global ecosystem.

prnewswire

Winner Medical

05:35 ET
			
			
				Dimora Medical Recognized as Key Driver in Winner Medical's Amazon Award

Health Care Supplies(IN40196.SH)

The A-share biopharmaceutical sector continues to strengthen, with Maccura, Hybribio Biotech, and KHB hitting the daily limit up in the afternoon. LIFERIVER and DAJY had previously reached their limit up, while WONDFO BIOTECH, ACROBIOSYSTEMS, Orient Biotech, and SSSW rose over 10%

MicroPort rose nearly 8% after issuing a profit warning, expecting to turn a profit last year

CETC Lantian Technology Launches Shanghai IPO

Alltest: Plans to repurchase company shares worth 100 million to 200 million yuan

Snibe: The company's myoglobin testing kit has obtained a medical device registration certificate